Navigation Links
Chemizon Announces Research Collaboration Expansion With Takeda
Date:10/1/2007

LONGMONT, Colo., Oct. 1 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070606/LAW174LOGO)

As part of the agreement, Chemizon will commit a majority of its current Korean site to the Takeda partnership. In addition, Chemizon will expand its Korean operations to accommodate future growth.

"Takeda is a premier global pharmaceutical company and we are delighted that they have chosen Chemizon as a preferred partner," said Dr. Tony Piscopio, Chairman and CEO of Chemizon. "Our highly motivated scientific team's commitment to excellence remains the foundation for Chemizon's rapid growth. As we add biology capabilities to our integrated discovery platform, our partners will be able to leverage a number of additional options that will become available in the near future."

About Chemizon Inc.:

Chemizon, a division of Optomagic Co. Ltd., is a global provider of drug discovery and development capabilities to the pharmaceutical industry. Anchored by an experienced management team, Chemizon combines its vertically integrated discovery platform with a flexible, collaborative business model to develop best-in-class clinical candidates. Our expertise spans a broad range of therapeutic areas and target classes. In addition to providing an integrated discovery solution, we assist our collaborators with stand alone services including: lead optimization, library design and synthesis, custom synthesis, radiolabeling, ADME profiling, analytical method development and process chemistry.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals.
'/>"/>

SOURCE Chemizon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Metamora, Michigan (PRWEB) May 30, 2015 ... procedure to lighten or stop periods, without the ... This procedure can reduce or stop menstrual bleeding and ... the uterus (the part that causes the bleeding), with ... million women suffer from heavy menstrual bleeding. Many ...
(Date:5/30/2015)... Diego, CA (PRWEB) May 30, 2015 ... is the lack of local healthcare options available. Often, ... to adequate healthcare. For those in rural areas feeling ... simply without health insurance or tired of paying high ... new E-consults, connecting patients with licensed physicians via the ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... EHO offers a suite of online applications ... the ability to manage their drug-spend for the lowest ... EHO has been able to compete with the big ... survive among the giants of the industry. Since EHO ... ago, it has simplified the way hospices can monitor ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2
... Michigan Comprehensive Cancer Center have identified a potential new way ... cells in a tumor that fuel its growth and spread. ... by a type of cell derived from bone marrow, called ... marrow to the cancer and create a "niche" for the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... 2011 - A recent study by Merikangas and colleagues ... Journal of the American Academy of Child and Adolescent ... that are affected with severely impairing mental disorders ever ... found that approximately one third of adolescents with any ...
... January 18, 2011 Heart disease is the leading cause ... States. But heart disease is more than just one disease; ... heart attack, high blood pressure, diabetes or other causes. In ... accumulation in heart cells. Obesity and high-fat diets are major ...
... the World Health Organisation (WHO), an estimated 322,000 deaths globally ... in many of these cases death could have been avoided ... major burn patients have insufficient skin left to graft on ... literally to be grown from the patient,s own skin cells. ...
... By Kathleen Doheny HealthDay Reporter , ... creams that promise "broad-spectrum" sun protection actually measure up, ... daytime moisturizers claiming to provide broad-spectrum protection from the ... reliable protection from harmful UV-A rays, which can penetrate ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
(Date:5/29/2015)... and MENLO PARK, Calif. , ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... proven cancer therapies in new orphan drug indications, ... Association of Cancer Research (AACR) Advances in Brain ... its lead product candidate VAL-083 (dianhydrogalactitol) ...
(Date:5/29/2015)... 29, 2015 Amgen (NASDAQ: AMGN ... Phase 3, global, randomized, placebo-controlled trials evaluating AMG ... secondary hyperparathyroidism (SHPT) in patients with chronic kidney ... primary endpoint, demonstrating that a greater proportion of ... greater than 30 percent reduction in parathyroid hormone ...
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... Amgen (Nasdaq: AMGN ) reported revenue unchanged ... $3,812 million for the third quarter of 2009. ... the third quarter of 2010 compared to $1,518 million for ... income was driven by unusually low research and development (R&D) ...
... 25 See video from Novartis: ... New Phase III data indicate that Menveo® (Meningococcal ... demonstrated robust immunogenicity in infants potentially offering protection ... 3. These data were presented during an oral ...
Cached Medicine Technology:Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 2Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 3Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 4Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 5Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 6Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 7Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 8Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 9Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 10Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 11Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 12Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 13Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 14Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year 15
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: